Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Human papillomavirus 16 (HPV16) and HPV52 E6-specific immunity in HIV-infected adults on combination antiretroviral therapy.

HIV medicine - 1 May 2017

Leng C Y, Low H C, Chua L L, Chong M L, Sulaiman H, Azwa I, Roberts J M, Kamarulzaman A, Rajasuriar R, Woo Y L

Abstract excerpt

OBJECTIVES: Human papillomavirus (HPV)-associated cancers disproportionately affect those infected with HIV despite effective combination antiretroviral therapy (cART). The primary aim of this study was to quantify HPV16 and HPV52 E6-specific interferon (IFN)-γ enzyme-linked immunospot (ELISPOT) T-cell responses, a correlate of protective immunity, in the first year following cART initiation and subsequently in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Retroviral Agents
Share to Antiretroviral Therapy, Highly Active

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enzyme-Linked Immunospot Assay

Share to Interferon-gamma

Share to Leukocytes, Mononuclear

Share to Oncogene Proteins, Viral

Share to Papillomaviridae

Share to Papillomavirus Infections

Source

Identifiers

PMID: 27649852
DOI: 10.1111/hiv.12432

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Human papillomavirus 16 (HPV16) and HPV52 E6-specific immunity in HIV-infected adults on combination antiretroviral therapy.PMID 27649852Read ↗

Association of High-Risk Human Papillomavirus with Genital Tract Mucosal Immune Factors in HIV-Infected Women.Semantic proximity Read ↗

Fast-Tracking HPV Clearance in Men: Adjunctive Pidotimod Enhances Response to HPV VaccinationSemantic proximity Read ↗

Human immunodeficiency virus type I-specific CD8+T cell subset abnormalities in chronic infection persist through effective antiretroviral therapySemantic proximity Read ↗

Incidence, clearance, and disease progression of genital human papillomavirus infection in heterosexual men.Semantic proximity Read ↗

Type-specific persistence and clearance rates of HPV genotypes in the oral and oropharyngeal mucosa in an HIV/AIDS cohort.Semantic proximity Read ↗

Combination antiretroviral therapy reduces the detection risk of cervical human papilloma virus infection in women living with HIV.Semantic proximity Read ↗

Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.Semantic proximity Read ↗

Harnessing CD8+ T Cells Under HIV Antiretroviral TherapySemantic proximity Read ↗

Frequent detection of HPV before and after initiation of antiretroviral therapy among HIV/HSV-2 co-infected women in Uganda.Semantic proximity Read ↗

Nonvaccine human papillomavirus genotype common in women with HIV failing cervical precancer treatment.Semantic proximity Read ↗

Immunoregulatory T Cells May Be Involved in Preserving CD4 T Cell Counts in HIV-Infected Long-Term Nonprogressors and ControllersSemantic proximity Read ↗

Immune checkpoint expression on HIV-specific CD4+ T cells and response to their blockade are dependent on lineage and functionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.